- Home
- ELAB vs ADIL Comparison
ELAB vs ADIL Comparison
Compare ELAB & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.70
Company Overview
Basic Information| Metric | ELAB | ADIL |
|---|---|---|
| Founded | 2020 | 2010 |
| Country | United States | United States |
| Employees | 34 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.1M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ELAB | ADIL |
|---|---|---|
| Price | $1.02 | $2.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 2.6M | 86.6K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.13 |
| 52 Week High | $15.00 | $5.17 |
Technical Indicators
Market Signals| Indicator | ELAB | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 35.93 | 51.03 |
| Support Level | $1.02 | $2.60 |
| Resistance Level | $1.56 | $2.98 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 4.46 | 26.81 |
Price Performance
Historical Comparison ELAB
ADIL
About ELAB Elevai Labs Inc.
PMGC Holdings Inc IS advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.